Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,

Exxon Chemical Co., a subsidiary of Exxon Mobil Corp., is an American company located in Buffalo Grove, IL, that manufactures and supplies specialty chemicals and provides services for oil and gas production, pipeline and drilling operations.

Shengyi Technology Co., Ltd. engages in the design, manufacturing and sale of copper-clad laminates, adhesive sheets, and printed circuit boards. Its products include copper-clad laminates, insulation laminates, metal-based copper-clad laminates, resin-coated copper foils, and cover films. The company was founded on June 27, 1985 and is headquartered in Dongguan, China.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Rhone Poulenc Rorer, a subsidiary of Solvay SA, is a French company that manufactures and distributs pharmaceutical products.

Nisshin Seifun Group, Inc. operates as a holding company which engages in the management of its group companies. It operates through the following segments: Flour Milling, Food Product, Meal and Side Dish, and Others. The Flour Milling segment offers wheat flour and bran products. The Food Product segment provides prepared mixes, wheat flour for consumer use, pasta, frozen and chilled foods, bakery and confectionery materials. The Meal and Side Dish segment includes prepared foods such as bento, side dishes, and cooked rice. The Others segment handles pet food, meshes, engineering, cargo handling and storage business. The company was founded by Teiichiro Shoda in October 1900 and is headquartered in Tokyo, Japan.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

Ningbo Shuxiang New Materials Co., Ltd., established on 2006-08-25, Business scope includes general items:High Strength Resin Matrix Composite Rail Insulation Components,Railway rail fasteners and rolling stock accessories,Anti-corrosion spiral spike,Lock nut,fastener,camouflage stealth material,Wave-transparent materials and products,Composite materials and products for vehicles,Development of ventilation equipment,manufacture,processing,Technical Consulting and Technical Services;Hardware,plastic products,Manufacture of molds and mechanical equipment,processing;Testing services for physical and chemical properties of composite materials;Ship technical service,technology R & D;Marine appliances,Ship accessories,electronic product,Instrumentation,Research and development of communication equipment,manufacture,processing(Another branch is set up for manufacturing and processing),wholesale,retail;Wujinjiaodian,Manufacture of electromechanical equipment and accessories,processing(Another branch is set up for manufacturing and processing),wholesale,retail;auto parts,building decoration materials,plastic products,Chemical raw materials and products(Removal of hazardous chemicals),computer accessories,office equipment,Stationery,crafts,Class I medical device,Wholesale of daily necessities,retail;aerospace equipment,Research and development of multi-spectrum camouflage stealth heavy-duty anti-corrosion coating,manufacture,processing,Technical Consulting and Technical Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

BASF AB supplies raw materials to paper, chemicals, and construction industries. Its products include construction chemical, crop protection products, dispersions and pigments, plastics, polyurethane systems and coating products. The company was founded in 1953 and is headquartered in Göteborg, Sweden.

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.

Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise, established by a team of returned PhD holders, which focuses on R&D of innovative medicines based on independent IPR, integrating R&D, manufacturing and marketing. Betta Pharmaceuticals has been dedicating to the R&D and manufacturing of National Class A new medicines with independent IPR. Betta Pharmaceuticals is a state-level hi-tech pharmaceutical enterprise, established by a team of returned PhD holders in 2003, which focuses on R&D of innovative medicines based on independent IPR, integrating R&D, manufacturing and marketing. Betta Pharmaceuticals has been dedicating to diseases severely influencing human health, e.g. malignant tumors, diabetes, and cardio-cerebrovascular disease. Its headquarters is located at Yuhang Economic and Technological Development Zone, Hangzhou City, with a pharmaceutical R&D center established in Beijing and Hangzhou respectively. At present, it boasts a team of nearly 1,000 employees, in which there are dozens of returned PhD holders with five of them included in The Recruitment Program of Global Experts of China. On Nov. 7th, 2016, Betta Pharmaceuticals was successfully listed in GEM of Shenzhen Stock Exchange. Betta has over 20 new drug development projects currently, among which its flagship product, Icotinib Hydrochloride (Conmana), has created several records: in Jul. 2012, it was involved in The International Annual Report on New Drug Research and Development, as the first targeted anti-cancer drug made in China; in Aug. 2013, Lancet Oncol, a world leading medical magazine, published a full text of China’s clinical research achievement of innovative drugs for the first time and commended that “Icotinib Hydrochloride has created the new era of China’s R&D of anti-cancer drugs”, according to the Editor’s Note; the compound and crystal form patents of Icotinib Hydrochloride won the Golden Prize of China Patent Award in 2012 and 2014 respectively; the R&D and industrialized achievement of Icotinib Hydrochloride won the First Prize of 2015 National Prize for Progress in Science and Technology, as the first time that this award was won by China’s chemical pharmaceutical industry and Zhejiang enterprise; in 2016, Icotinib Hydrochloride (Conmana) won the highest award of China’s industrial area, China Grand Award for Industry. The Company possesses over 100 authorized patents with other hundreds of patents applied in process; sets 4 technical standards, in which the standard for Icotinib Hydrochloride crude drugs and tablets has turned into national standard; won national special award of Key Formulation of New Drugs for several times and was involved in MOST National High-tech R&D Program (863 Program), China Torch Program and National Strategic Innovative Product. Independent R&D, strategic cooperation and marketing are the three driving factors promoting the better and faster development of Betta, laying a solid foundation for the realization of its strategic vision of “turning into a transnational pharmaceutical enterprise headquartered in China”. Innovation is of no bounds. Betta Pharmaceuticals will continue to carry forward its development concept as pioneering innovation to the benefit of the public, devote itself to innovation for the public and technology development benefiting the public by means of development of new medicines, to provide Chinese residents with more affordable medicines of good quality.

Guangdong Hebo Pharmaceutical Co., Ltd., established on 2013-11-25, Business scope includes pharmaceutical production;Pharmaceutical business;second,Three types of medical device manufacturers;second,Three types of medical device operating enterprises;Chemical raw materials,chemical preparation,Biological product,Health food research and development;chemical technology,Medical Technology,Biological Technology,Technology research and development of medical devices,Technical consulting and technology transfer;Pharmaceutical Industry Investment;Import and export of goods and technology(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sumitomo Chemical Co. Ltd. is a Japanese company that produces and markets various types of chemicals. The company’s business sectors include petrochemicals and plastics, energy and functional materials, IT-related chemicals, health and crop sciences, and pharmaceuticals. Its portfolio of products includes propylene oxide, caprolactam, polypropylene, polyethylene, methyl methacrylate polymer, alumina, aluminum, resorcinol, synthetic rubber, polarizing films, photoresists, super engineering plastics, lithium-ion secondary battery materials, crop protection chemicals, feed additives, products for control of infectious diseases, and more. The firm manages two companies in the pharmaceutical sector: Sumitomo Dainippon Pharma Co., Ltd., engaged in the prescription pharmaceuticals business; and Nihon Medi-Physics Co., Ltd., engaged in the diagnostic pharmaceuticals business. Sumitomo Chemical Co. Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

Dongying Yuelai Lake Park Operation Management Co., Ltd., established on 2019-04-15, Business scope includes park operation and management;commercial service(Security service not included);Entrepreneurial Consulting Services;Talent introduction,Transformation of scientific and technological achievements;Business Management Consulting Services;Technology promotion and application services;Conference and exhibition services,Cleaning Services;Landscape Engineering,Own house rental.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

China Petrochemical Corporation (Sinopec Group) is a super-large petroleum and petrochemical enterprise group, established in July 1998 on the basis of the former China Petrochemical Corporation. Sinopec Group is a state-owned company solely invested by the state, functioning as a state-authorized investment organization in which the state holds the controlling share. Headquartered in Beijing, Sinopec Group has a registered capital of RMB 231.6 billion. The board chairman of Sinopec Group is its legal representative. Sinopec Group executes the investor rights over related state assets owned by its full subsidiaries, controlled companies and share-holding companies. These rights include receiving returns on assets, making major decisions and appointing management teams. The Group operates, manages and supervises state assets according to related laws, and shoulders the corresponding responsibility of maintaining and increasing the value of state assets. China Petroleum and Chemical Company (Sinopec Corp.), controlled by Sinopec Group, issued H-shares and A-shares at overseas and home respectively in October 2000 and August 2001 and was listed on stock markets in Hong Kong, New York, London and Shanghai. Sinopec Group’s key business activities include: industrial investment and investment management; the exploration, production, storage and transportation (including pipeline transportation), marketing and comprehensive utilization of oil and natural gas; the production, marketing, storage and transportation of coal; oil refining; the storage, transportation ,wholesale and retail of oil products; the production, marketing, storage, transportation of petrochemicals, natural gas chemicals, coal chemicals and other chemical products; the exploration, design, consulting, construction and installation of petroleum and petrochemical engineering projects; the overhaul and maintenance of petroleum and petrochemical equipments; the research and development, manufacturing and marketing of electrical and mechanical equipments; the production and marketing of electricity, steam, water and industrial gas; the research, development, application and consulting services of technology, e-business, information and alternative energy products; the import and export of self-support and agent commodity and technology; foreign project contracting, invite bidding, labor export; the international storage and logistics business. Sinopec Group ranked the 3rd in the Fortune Global 500 in 2014.

Chengdu Maha Dalong Pharmaceutical Technology Co., Ltd., established on 2022-02-10, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Specialty Chemicals Sales(Free of Hazardous Chemicals);Information Consulting Service(Not including licensing information consulting services);Business Management Consulting.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)